| Literature DB >> 30581503 |
Zeinab Barartabar1, Abdolrahim Nikzamir1, Majid Sirati-Sabet1, Elham Aghamohammadi2, Vahid Chaleshi2, Mohammad Rostami Nejad2, Hamid Asadzadeh-Aghdaei3, Mohammad Reza Zali2.
Abstract
INTRODUCTION: Celiac disease (CD) is a chronic inflammatory intestinal disorder. Different immunological factors, including inflammatory cytokines, may play an important role in disease susceptibility. AIM: To investigate the relationship between -174G/C and -572G/C gene polymorphisms and the serum level of interleukin 6 (IL-6) and susceptibility to CD in the Iranian population.Entities:
Keywords: IL-6 gene polymorphism; autoimmune and inflammatory reaction; celiac disease; polymerase chain reaction-restriction fragments length polymorphism
Year: 2018 PMID: 30581503 PMCID: PMC6300853 DOI: 10.5114/pg.2018.79808
Source DB: PubMed Journal: Prz Gastroenterol ISSN: 1895-5770
Size of fragments produced by restriction enzyme
| Enzyme | Restriction site | Genotype | Fragment length [bp] |
|---|---|---|---|
| SfaNI | GCATC | CC | 442 |
| GG | 379, 63 | ||
| CG | 442, 379 and 63 | ||
| BsrBI | CCGCTC | CC | 358 |
| GG | 285 and 73 | ||
| CG | 358, 285, and 73 |
Figure 1Sequence of rs1800795
Figure 2Sequence of rs1800796
Genotypic and allelic frequency of IL-6 promoter polymorphism (-174) and (-572) in patients with CD and healthy controls
| Variable | Genotype and allele | Celiac patient ( | Healthy control ( | CI | OR | |
|---|---|---|---|---|---|---|
| rs1800795 | GG | 47 (44.8%) | 61 (57.5%) | Ref. | Ref. | Ref. |
| CC | 11 (10.5%) | 5 (4.7%) | 0.372–1.157 | 0.656 | 0.145 | |
| CG | 47 (44.8%) | 40 (37.7%) | 0.114–1.077 | 0.35 | 0.06 | |
| G | 141 (67.1%) | 162 (76.4%) | Ref. | Ref. | Ref. | |
| C | 69 (32.9%) | 50 (23.6%) | 0.411–0.968 | 0.631 | 0.034 | |
| rs1800796 | GG | 38 (36.2%) | 12 (11.3%) | Ref. | Ref. | Ref. |
| CG | 60 (57.1%) | 90 (84.9%) | 0.451–7.260 | 1.810 | 0.403 | |
| CC | 7 (6.7%) | 4 (3.8%) | 2.297– 9.823 | 4.750 | < 0.001 | |
| G | 136 (64.8%) | 114 (53.8%) | Ref. | Ref. | Ref. | |
| C | 74 (35.2%) | 98 (46.2%) | 1.068–2.336 | 1.580 | 0.022 |
Figure 3Relationship between serum levels in CD patients and healthy subjects